Alnylam Pharmaceuticals said this week that it has launched the InterfeRx licensing program for its RNAi intellectual property.

The program, said the com- pany, will grant licenses for the development of RNAi therapeutics under Alnylam’s portfolio of issued and pending patents. One of those, which Alnylam holds exclusively, is the so-called Tuschl-2 patent application. This IP describes the two-to-three nucleotide 3’ overhanging ends on the end of certain siRNAs used for RNAi.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.

Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.

Researchers link genetic links between education and smoking and longevity.

In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.